These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299 [TBL] [Abstract][Full Text] [Related]
12. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Wang J; Cai Y; Ren C; Ittmann M Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141 [TBL] [Abstract][Full Text] [Related]
13. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293 [TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128 [TBL] [Abstract][Full Text] [Related]
15. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517 [TBL] [Abstract][Full Text] [Related]
16. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Shah RB; Chinnaiyan AM Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877 [TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
18. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455 [TBL] [Abstract][Full Text] [Related]
19. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Hermans KG; van der Korput HA; van Marion R; van de Wijngaart DJ; Ziel-van der Made A; Dits NF; Boormans JL; van der Kwast TH; van Dekken H; Bangma CH; Korsten H; Kraaij R; Jenster G; Trapman J Cancer Res; 2008 Sep; 68(18):7541-9. PubMed ID: 18794142 [TBL] [Abstract][Full Text] [Related]
20. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]